论文部分内容阅读
目的利用敏感性分析评价中国急性冠状动脉综合征(ACS)患者使用替格瑞洛与氯吡格雷的成本-效果。方法采用单因素敏感性分析方法,在现有研究基础上,结合2014年全国31个地区的生产总值数据,对替格瑞洛相比氯吡格雷的经济性进行敏感性分析。结果在参数变动范围内,替格瑞洛相比氯吡格雷治疗ACS的增量成本效果比(ICER)小于绝大多数地区的人均国内生产总值(GDP)(甘肃、贵州除外),且均小于31个地区的3倍人均GDP。结论基于2014年数据,替格瑞洛相比氯吡格雷治疗ACS在全国31个地区均更具成本-效果。
Objective To evaluate the cost-effectiveness of ticagrelor and clopidogrel in Chinese patients with acute coronary syndrome (ACS) using a sensitivity analysis. Methods The sensitivity of ticagrelor compared with that of ticagrelor was analyzed by single factor sensitivity analysis and based on the existing research and the data of GDP in 31 districts of China in 2014. Results The ICER of ticagrelor versus clopidogrel was less than the per capita gross domestic product (except Gansu and Guizhou) in the vast majority of regions within the parameter range and both 3 times the GDP per capita in less than 31 regions. Conclusion Based on 2014 data, ticagrelor vs clopidogrel was more cost-effective in 31 districts throughout the country.